Centene price target lowered to $93 from $100 at Barclays

Barclays analyst Steve Valiquette lowered the firm’s price target on Centene to $93 from $100 and keeps an Overweight rating on the shares following the Q4 earnings beat. As expected for the 2023 outlook, the shift in redetermination timing from February to April and marketplace growth offset by softer Medicare Advantage growth drove a net premium raise of $2B, the analyst tells investors in a research note.